MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster ...

Arbutus Biopharma Corporation announced that five abstracts, including a late-breaker, have been accepted for poster presentations at the EASL Congress 2025 in Amsterdam from May 7 to 10, 2025. The ...

Affimed N.V., a clinical-stage immuno-oncology company, announced that an abstract on its phase 2 LuminICE-203 study involving the innate cell engager acimtamig in combination with AlloNK has been ...

The American Society for Engineering Education (ASEE) Rocky Mountain Section (RMS) invites the submission of papers, extended abstracts, presentations, posters, workshops and lightning talks for the ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology, today announced that a late-breaking abstract featuring data for the company’s NeXT Personal ® whole ...

Call for submissions is from 15th of January to 15th of February 2026. Link to the submission platform and guidance for submitting will be updated. There will be 3 presentation formats at the meeting, ...

Contributions on the topics listed above are welcome as poster presentations. All submissions, apart from invited papers, must present original work, which has not been published elsewhere. In ...

Contributions on the topics listed in the Conference Announcement under Section C are welcome as oral or poster presentations. All submissions, apart from invited papers, must present original work, ...

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in ...